GLP-1 agonists offer dual benefits for psoriasis and hidradenitis suppurativa patients with obesity — reducing weight and potentially improving inflammatory skin disease driven by chronic low-grade inflammation.
Dual benefit: weight + inflammationGLP-1 agonists may break the obesity-inflammation cycle driving psoriasis and hidradenitis severity
What the researchers found
GLP-1 receptor agonists offer weight loss and potential anti-inflammatory benefits for patients with psoriasis or hidradenitis suppurativa complicated by obesity, addressing a key driver of disease severity.
Why it matters
Many psoriasis and HS patients are trapped in an obesity-inflammation cycle that worsens both conditions. GLP-1 drugs could break this cycle by reducing both weight and inflammation — a dual benefit that existing dermatology treatments don't provide.
The numbers in context
GLP-1 drugs produce greater weight loss than previous pharmacological options; psoriasis and HS are often associated with obesity.
How the study worked
Clinical review covering pharmacological obesity management in immune-mediated skin diseases, with focus on GLP-1 agonist mechanisms and clinical evidence.
Who was studied
Patients with psoriasis or hidradenitis suppurativa and comorbid obesity
What this study cannot tell us
Review article — no clinical trial data specific to GLP-1 use in dermatology patients. Direct anti-inflammatory effects on skin diseases are theoretical. Insurance coverage for GLP-1 drugs is often limited to diabetes/obesity indications. Long-term weight maintenance and skin disease outcomes unknown.
How to read the evidence
Preliminary evidence — review based on established GLP-1 weight loss data and known obesity-skin disease associations, but no dedicated dermatology GLP-1 trials referenced.
When this study was published
Published in 2024 (translated article). Timely as GLP-1 drugs expand beyond diabetes and obesity indications.
The bigger picture
Dermatology is beginning to recognize that treating metabolic comorbidities like obesity isn't just 'nice to have' — it may be essential for optimal skin disease management. GLP-1 drugs represent a convergence of metabolic and dermatologic treatment that could reshape how inflammatory skin diseases are managed.
Questions still open
- Do GLP-1 agonists directly improve psoriasis or HS independent of weight loss?
- Should dermatologists be prescribing or recommending GLP-1 drugs for obese patients with inflammatory skin diseases?
- Can weight loss with GLP-1 drugs reduce the need for biologic therapy in psoriasis?
Common questions
Can weight loss drugs help with skin diseases like psoriasis?
Why does being overweight make psoriasis worse?
Read the original research
[Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases.
Actas dermo-sifiliograficas, 115(1), T56-T65
Citation
Vilarrasa, E; Nicolau, J; de la Cueva, P; Goday, A; Gallardo, F; Martorell-Calatayud, A; Carrascosa, J M. (2024). [Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases.. Actas dermo-sifiliograficas, 115(1), T56-T65. https://doi.org/10.1016/j.ad.2023.10.019